Potential Role of Adiponectin Receptor Agonist, AdipoRon in Cardiometabolic Disease
2019
Eunhee Cho | Sewon Lee
PURPOSE Adiponectin has beneficial effects on metabolic and cardiovascular disease. Adiponectin receptor agonist, AdipoRon was discovered in 2013 and it may play an important role in preventing and ameliorating cardiometabolic disease. However, the physiological function and signal transduction of AdipoRon are still under way, and the potential role of AdipoRon in metabolic and cardiovascular diseases has not been clearly elucidated. The purpose of this review is to provide basic knowledge for the potential role of AdipoRon in cardiometabolic disease. METHODS In this review, we summarized the previous studies (published between 2013 and 2019) investigating the effect of AdipoRon on metabolic and cardiovascular disease. RESULTS The previous evidences have shown that AdipoRon treatment exerted its pleiotropic actions on metabolism related tissue and organs including adipose tissue, skeletal and cardiac muscles, liver, kidney, and vascular beds. Activation of adiponectin receptors may be effective for the treatment of metabolic and cardiovascular diseases due in part to activation of AMPK and PPARα signaling pathway as adiponectin does. CONCLUSIONS In conclusion, AdipoRon can be a novel therapeutic agent for the cardiometabolic disease. However, all of previous studies were conducted using experimental animal models and it is needed to investigate the role of AdipoRon in metabolic and cardiovascular disease in human.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals